Publications by authors named "Frits Van Rhee"

100Publications

Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials.

Lancet Haematol 2020 Mar 3;7(3):e209-e217. Epub 2020 Feb 3.

Center for Personalized Therapy and Clinical Trials Office, UC San Diego Moore's Cancer Center, La Jolla, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(19)30257-1DOI Listing
March 2020

A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.

Blood Adv 2020 01;4(1):181-190

Center for Genetic Epidemiology, Department of Preventive Medicine, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2019000491DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6960456PMC
January 2020

Storming the Castle with TCP.

Blood 2019 04;133(16):1697-1698

University of Arkansas for Medical Sciences.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/lookup/doi/10.1182/blood-2019-02
Publisher Site
http://dx.doi.org/10.1182/blood-2019-02-900803DOI Listing
April 2019

Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data.

Br J Haematol 2019 01 11;184(2):232-241. Epub 2018 Sep 11.

Division of Translational Medicine and Human Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/bjh.15588
Publisher Site
http://dx.doi.org/10.1111/bjh.15588DOI Listing
January 2019

MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma.

BMC Cancer 2018 Jul 6;18(1):724. Epub 2018 Jul 6.

Myeloma Institute, University of Arkansas for Medical Sciences, Winthrop P. Rockefeller Cancer Institute, 4301 West Markham St., Slot 776, Rm 914, Little Rock, AR, 72205, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-018-4602-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6035431PMC
July 2018

Infectious and immunological sequelae of daratumumab in multiple myeloma.

Br J Haematol 2019 04 5;185(1):187-189. Epub 2018 Jul 5.

Division of Infectious Diseases, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15433DOI Listing
April 2019

Daratumumab for POEMS Syndrome.

Mayo Clin Proc 2018 04;93(4):542-544

University of Arkansas for Medical Sciences, Little Rock, AR.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00256196183009
Publisher Site
http://dx.doi.org/10.1016/j.mayocp.2018.02.001DOI Listing
April 2018

Myeloid transformation of plasma cell myeloma: molecular evidence of clonal evolution revealed by next generation sequencing.

Diagn Pathol 2018 Feb 20;13(1):15. Epub 2018 Feb 20.

Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR, 72205-7199, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13000-018-0692-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819706PMC
February 2018

Castleman Disease.

Hematol Oncol Clin North Am 2018 02;32(1):xiii-xiv

Dana Farber Cancer Institute, VA Boston Healthcare System, Harvard Medical School, 450 Brookline Avenue, M230, Boston, MA 02215, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2017.10.001DOI Listing
February 2018

Treatment of Idiopathic Castleman Disease.

Hematol Oncol Clin North Am 2018 02;32(1):89-106

UAMS Myeloma Institute, University of Arkansas for Medical Sciences, 4301 West Markham, #816, Little Rock, AR 72205, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2017.09.008DOI Listing
February 2018

Immunologic approaches for the treatment of multiple myeloma.

Cancer Treat Rev 2017 Apr 6;55:190-199. Epub 2017 Apr 6.

Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2017.03.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604432PMC
April 2017

Transplantation for Multiple Myeloma.

Cancer Treat Res 2016;169:227-250

Stem Cell and Allogeneic Transplant, Department of Hematology/Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-40320-5_13DOI Listing
June 2017

Idiopathic multicentric Castleman's disease: a systematic literature review.

Lancet Haematol 2016 Apr 17;3(4):e163-75. Epub 2016 Mar 17.

Orphan Disease Center, Perelman School of Medicine, University of Pennsylvania, Translational Research Laboratory, Philadelphia, PA, USA; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://www.thelancet.com/pdfs/journals/lanhae/PIIS2352-3026(
Web Search
http://dx.doi.org/10.1016/S2352-3026(16)00006-5DOI Listing
April 2016

Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?

Immunotherapy 2016 17;8(3):367-84. Epub 2016 Feb 17.

Myeloma Institute, University of Arkansas for Medical Sciences, 4301 West Markham, Little Rock, AR 72205, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt.15.118DOI Listing
December 2016

Atrial Fibrillation in Hematologic Malignancies, Especially After Autologous Hematopoietic Stem Cell Transplantation: Review of Risk Factors, Current Management, and Future Directions.

Clin Lymphoma Myeloma Leuk 2016 Feb 24;16(2):70-5. Epub 2015 Oct 24.

Department of Hematology and Oncology, Myeloma Institute, University of Arkansas Medical Sciences, Little Rock, AR.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2015.10.001DOI Listing
February 2016

Profile of elotuzumab and its potential in the treatment of multiple myeloma.

Blood Lymphat Cancer 2014 Jun;2014(4):15-27

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BLCTT.S49780DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4438995PMC
June 2014

Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocols.

Clin Case Rep 2015 Mar 13;3(3):183-92. Epub 2015 Feb 13.

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences 4301 West Markham Slot 816, Little Rock, Arkansas, 72205.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ccr3.180
Publisher Site
http://dx.doi.org/10.1002/ccr3.180DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4377252PMC
March 2015

Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients.

J Immunother 2015 Jan;38(1):24-36

*Myeloma Institute for Research and Therapy §Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR †Center for Cell and Gene Therapy, The Methodist Hospital, Texas Children's Hospital, Houston, TX ‡Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore ∥Department of Pediatrics, Baylor College of Medicine, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CJI.0000000000000059DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352951PMC
January 2015

Haematological cancer: Optimizing the treatment of multiple myeloma.

Nat Rev Clin Oncol 2014 Dec 28;11(12):686-8. Epub 2014 Oct 28.

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 West Markham, Slot 816, Little Rock, AR 72205, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2014.185DOI Listing
December 2014

Curing myeloma at last: defining criteria and providing the evidence.

Blood 2014 Nov 7;124(20):3043-51. Epub 2014 Oct 7.

Cancer Research And Biostatistics, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2014-07-552059DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231416PMC
November 2014

Siltuximab for multicentric Castleman disease.

Expert Rev Hematol 2014 Oct 9;7(5):545-57. Epub 2014 Aug 9.

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 West Markham, Little Rock, AR 72205, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17474086.2014.946402DOI Listing
October 2014

Clinical grade purification and expansion of natural killer cells.

Crit Rev Oncog 2014 ;19(1-2):121-32

Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4095851PMC
http://dx.doi.org/10.1615/critrevoncog.2014010931DOI Listing
September 2014

The future of autologous stem cell transplantation in myeloma.

Blood 2014 Jul 3;124(3):328-33. Epub 2014 Jun 3.

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR; and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2014-03-561985DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102706PMC
July 2014

Engineering more efficacious antibody therapy for myeloma.

Authors:
Frits van Rhee

Blood 2014 May;123(20):3062-3

UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2014-04-560342DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023414PMC
May 2014

In multiple myeloma, 14q32 translocations are nonrandom chromosomal fusions driving high expression levels of the respective partner genes.

Genes Chromosomes Cancer 2014 Jul 17;53(7):549-57. Epub 2014 Mar 17.

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W. Markham St, Little Rock, AR, 72205.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gcc.22165DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4016160PMC
July 2014

HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy.

Blood 2014 May 12;123(19):2924-33. Epub 2014 Mar 12.

Center for Orphan Disease Research and Therapy, Raymond and Ruth Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2013-12-545087DOI Listing
May 2014

A compound T60A and V122I heterozygosity in the transthyretin gene causing early onset severe cardiac amyloidosis.

Amyloid 2014 Jun 11;21(2):134-5. Epub 2014 Feb 11.

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences , Little Rock, AR , USA .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/13506129.2014.883373DOI Listing
June 2014

Efficient lysis of epithelial ovarian cancer cells by MAGE-A3-induced cytotoxic T lymphocytes using rAAV-6 capsid mutant vector.

Vaccine 2014 Feb 6;32(8):938-43. Epub 2014 Jan 6.

Laboratory of Surgical Oncology & Developmental Therapeutics, Department of Surgery, Wayne State University, Detroit, MI, USA; John D. Dingell VA Medical Center, Detroit, MI, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0264410X130179
Publisher Site
http://dx.doi.org/10.1016/j.vaccine.2013.12.049DOI Listing
February 2014

Patterns of central nervous system involvement in relapsed and refractory multiple myeloma.

Clin Lymphoma Myeloma Leuk 2014 Jun 16;14(3):211-4. Epub 2013 Nov 16.

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2013.11.004DOI Listing
June 2014

Homozygosity for the V122I mutation in transthyretin is associated with earlier onset of cardiac amyloidosis in the African American population in the seventh decade of life.

J Mol Diagn 2014 Jan 30;16(1):68-74. Epub 2013 Oct 30.

Laboratory of Molecular Genetics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmoldx.2013.08.001DOI Listing
January 2014

Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma.

PLoS One 2013 16;8(9):e74191. Epub 2013 Sep 16.

Myeloma Institute for Research and Therapy, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0074191PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3774816PMC
May 2014

Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease.

Am J Hematol 2013 Jun 28;88(6):463-71. Epub 2013 Mar 28.

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.23433DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3971999PMC
June 2013

NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity.

Exp Hematol 2013 Jun 19;41(6):547-557.e2. Epub 2013 Feb 19.

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exphem.2013.02.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648259PMC
June 2013

Eruptive cherry hemangiomatosis associated with multicentric Castleman disease: a case report and diagnostic clue.

JAMA Dermatol 2013 Feb;149(2):204-8

Perelman School of Medicine, University of Pennsylvania, PA 19104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamadermatol.2013.1552DOI Listing
February 2013

Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy.

Clin Adv Hematol Oncol 2010 Jul;8(7):486-98

University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy, Little Rock, AR 72205, USA.

View Article

Download full-text PDF

Source
July 2010

Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.

J Clin Oncol 2010 Aug 12;28(23):3701-8. Epub 2010 Jul 12.

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 West Markham, Little Rock, AR 72205, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2009.27.2377DOI Listing
August 2010

Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms.

J Clin Oncol 2010 Jun 17;28(18):3023-7. Epub 2010 May 17.

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2009.26.4465DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2903335PMC
June 2010

Light-chain MGUS: implications for clinical practice.

Authors:
Frits van Rhee

Lancet 2010 May;375(9727):1670-1

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(10)60707-6DOI Listing
May 2010

High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2.

Proc Natl Acad Sci U S A 2010 Apr 12;107(17):7904-9. Epub 2010 Apr 12.

Donna D and Donald M Lambert Laboratory for Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.0908441107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2867889PMC
April 2010

Turning up the heat on myeloma.

Authors:
Frits van Rhee

Blood 2009 Oct;114(18):3724-5

University of Arkansas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2009-08-238139DOI Listing
October 2009